BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27923207)

  • 21. Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study.
    Chang CH; Lin JW; Chen ST; Lai MS; Chuang LM; Chang YC
    Medicine (Baltimore); 2016 Feb; 95(7):e2603. PubMed ID: 26886601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
    Horsdal HT; Mehnert F; Rungby J; Johnsen SP
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.
    Andersson C; Olesen JB; Hansen PR; Weeke P; Norgaard ML; Jørgensen CH; Lange T; Abildstrøm SZ; Schramm TK; Vaag A; Køber L; Torp-Pedersen C; Gislason GH
    Diabetologia; 2010 Dec; 53(12):2546-53. PubMed ID: 20838985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
    Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
    Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sitagliptin and the risk of hospitalization for heart failure: a population-based study.
    Wang KL; Liu CJ; Chao TF; Huang CM; Wu CH; Chen SJ; Yeh CM; Chen TJ; Lin SJ; Chiang CE
    Int J Cardiol; 2014 Nov; 177(1):86-90. PubMed ID: 25499347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
    Eurich DT; Majumdar SR; McAlister FA; Tsuyuki RT; Johnson JA
    Diabetes Care; 2005 Oct; 28(10):2345-51. PubMed ID: 16186261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.
    Roumie CL; Min JY; D'Agostino McGowan L; Presley C; Grijalva CG; Hackstadt AJ; Hung AM; Greevy RA; Elasy T; Griffin MR
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28424149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
    Fadini GP; Saragoni S; Russo P; Degli Esposti L; Vigili de Kreutzenberg S; Melazzini M; Avogaro A;
    Diabetes Obes Metab; 2017 Oct; 19(10):1416-1424. PubMed ID: 28432754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
    He S; Qian X; Chen Y; Shen X; Zhang B; Chen X; Xu X; Li G
    J Diabetes Res; 2021; 2021():5534387. PubMed ID: 34222493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
    Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
    Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
    McAlister FA; Eurich DT; Majumdar SR; Johnson JA
    Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study.
    Chen JM; Chang CW; Lin YC; Horng JT; Sheu WH
    J Diabetes Res; 2014; 2014():812628. PubMed ID: 25197673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
    Karter AJ; Ahmed AT; Liu J; Moffet HH; Parker MM
    Diabet Med; 2005 Aug; 22(8):986-93. PubMed ID: 16026362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
    Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
    Garratt KN; Brady PA; Hassinger NL; Grill DE; Terzic A; Holmes DR
    J Am Coll Cardiol; 1999 Jan; 33(1):119-24. PubMed ID: 9935017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.
    Grimes RT; Bennett K; Tilson L; Usher C; Smith SM; Henman MC
    Br J Clin Pharmacol; 2015 Jun; 79(6):1000-9. PubMed ID: 25521800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan.
    Hsiao FY; Tsai YW; Wen YW; Chen PF; Chou HY; Chen CH; Kuo KN; Huang WF
    Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):786-91. PubMed ID: 20607752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.